Subscribe Become an Author Sign Up Log In

Biopharma news

Section: Biopharma Insights     View all sections


Pharma and Healthcare AI Vendors Join Forces To Accelerate Progress In Drug Discovery

   by Andrii Buvailo    2308
Pharma and Healthcare AI Vendors Join Forces To Accelerate Progress In Drug Discovery

Today Basel is crowded with some of the top business and research leaders representing a young and rapidly growing industry of artificial intelligence (AI) in healthcare and pharmaceutical research. They come together to announce mission and launch activities of a global Alliance for Artificial Intelligence in Healthcare (AAIH), which is to become a leading international organization for advancing artificial intelligence innovations in Drug Discovery, Clinical Research, Diagnostics, Precision Medicine and other key areas of pharmaceutical research and healthcare. The newly formed alliance will be a voice of the industry in matters of education, lobbying for policies and regulations, facilitating investment, and promoting AI-innovations among top drug makers and healthcare institutions.

A Second Chance for Integrins: Biotech Startup Morphic Therapeutic Reinvents Old Target

   by Andrii Buvailo    1879
A Second Chance for Integrins: Biotech Startup Morphic Therapeutic Reinvents Old Target

Integrins are a group of transmembrane receptors playing a major role in cell-cell and cell-extracellular matrix (ECM) interactions. When triggered, integrin receptors transduce signals to the interior of the cell, providing quick and flexible “status update” about chemical composition and mechanical status of the ECM. It results in a cellular response, such as a change in the cell shape, regulation of the cell cycle, adjusting motility, or adding new receptors to the cell membrane.

Facebook and Napster founder Sean Parker is going to “hack cancer” by CRISPR technology

   by Andrii Buvailo    1887
Facebook and Napster founder Sean Parker is going to “hack cancer” by CRISPR technology

A billionaire Sean Parker, known as a founder of Facebook and Napster, has steeply entered Life Sciences industry to fund the world’s first-ever CRISPR/Cas9 trial, backed by US federal authorities. Upon success, the probability of which is now hard to assess, this technology can revolutionize the way cancer and many other diseases are treated. This time, Sean Parker is playing a bigger game than ever, however, uncertainty is huge.